Federal Register #2026-17156

License Opportunity: Matched Patient-Derived IDH-Mutant Glioma Cell Lines from NIH/NCI

The Department of Health and Human Services, via the National Institutes of Health (NIH) and its Center for Scientific Review, is offering a license opportunity for government-owned research materials. - OEM Highlight: - National Institutes of Health (NIH), specifically the National Cancer Institute (NCI) - Products/Research Materials: - Matched patient-derived 3D Isocitrate Dehydrogenase (IDH)-mutant glioma cell lines, designated 403L and 403H - NIH Reference Number: E1452026 - Developed from the same patient before and after malignant transformation (WHO grade 2 to grade 4) - Intended Applications: - Oncology and neurology research - Molecular classification, diagnostic subtyping, clinical trial stratification, and cancer treatment development - Unique Requirements: - No specific purchase quantities; opportunity is for licensing the cell lines as research tools - Cell lines are matched and derived from a unique patient case, enhancing research value - Additional Information: - Notice also references closed meetings for grant review, but procurement is focused on cell line licensing

Description

The National Institutes of Health's Center for Scientific Review announces a series of closed meetings to review and evaluate grant applications. These meetings will be held virtually and cover various scientific review groups and study sections, focusing on topics such as behavioral health, infectious diseases, cell biology, endocrinology, emerging technologies, and cancer therapeutics. The meetings are closed to the public due to the confidential nature of the grant applications, which may include trade secrets and personal information. The meetings are scheduled between September 24, 2026, and October 29, 2026.

View original listing